Opioid Co. Inks $1.6M Deal To End Suit Over FDA Rejection
Canadian drugmaker Intellipharmaceutics International Inc. has agreed to pay investors $1.6 million to settle a proposed class action alleging the company overstated opioid painkiller Rexista's ability to deter abuse before the U.S....To view the full article, register now.
Already a subscriber? Click here to view full article